BMJ Case Reports 2018; doi:10.1136/bcr-2017-223611
  • Novel treatment (new drug/intervention; established drug/procedure in new situation)

Treatment of relapsed multiple myeloma complicated by cardiac extramedullary plasmacytoma with D-PACE chemotherapy

  1. Daniel Pinkhas
  1. Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio, USA
  1. Correspondence to Dr Corey Toocheck, toocheck.corey{at}
  • Accepted 14 February 2018
  • Published 9 March 2018


Cardiac extramedullary plasmacytomas (EMPs) are rare and may be a seen as a complication of multiple myeloma (MM) or in isolation. Here, we describe a case of cardiac EMP that presented clinically as a congestive heart failure exacerbation in a patient with relapsed and refractory IgG lambda MM. We highlight radiographic imaging in conjunction with laboratory biomarkers at presentation and in response to D-PACE (dexamethasone, cisplatin (Platinol), doxorubicin (Adriamycin), cyclophosphamide and etoposide) systemic chemotherapy.


  • Contributors CT was responsible for composing and revising this manuscript as well as literature review. He is the guarantor. DP was responsible for writing and revising this manuscript. CT and DP provided direct care for the patient.

  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog

Navigate This Article